Home/Pipeline/Buloxibutid (C21)

Buloxibutid (C21)

Idiopathic Pulmonary Fibrosis (IPF)

Phase 2bActive, Now EnrollingNCT06588686

Key Facts

Indication

Idiopathic Pulmonary Fibrosis (IPF)

Phase

Phase 2b

Status

Active, Now Enrolling

Company

Vicore Pharma

About Vicore Pharma

Vicore Pharma is an innovative, clinical-stage biopharma company dedicated to developing transformative treatments by selectively activating the protective angiotensin II type 2 (AT2) receptor. Its core achievement is advancing buloxibutid, a first-in-class oral AT2 receptor agonist, into a pivotal 52-week global Phase 2b trial (ASPIRE) in Idiopathic Pulmonary Fibrosis (IPF), supported by Orphan Drug and Fast Track designations. The company's strategy is to validate its ATRAG platform in IPF as a proof-of-concept, aiming to unlock its broad therapeutic potential across multiple fibrotic and inflammatory diseases while exploring strategic partnerships for pipeline expansion.

View full company profile

Therapeutic Areas

Idiopathic Pulmonary Fibrosis Fibrotic Diseases Respiratory Diseases

Other Idiopathic Pulmonary Fibrosis (IPF) Drugs

Drug	Company	Phase	Status
OATD-01	Molecure	Phase II	Active, recruiting
FP-020 (BMS-986235)	Foresee Pharmaceuticals	Phase 2	Active
AP02	Avalyn Pharmaceuticals	Phase 2	Active
Gento-Fibrose Pulmonaire Program	Genoscience Pharma	Preclinical	Active
SM001 (alidornase/Tigerase)	SarcoMed USA	Research	Active
NLM-001	Nelum Pharma	Phase 1	Active
GNS-3545 (ROCK2 Inhibitor)	Genosco	Phase 1	Active
TG2 Inhibitor Program	Isterian Biotech	Preclinical	Active
Taladegib (ENV-101)	Endeavor BioMedicines	Phase 2b	Active
CAL101	Calluna Pharma	Phase 2	Active
NVP-13	Velvio	Pre-clinical	Active
LASN01	Lassen Therapeutics	Preclinical	Active